UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

TP021/#1521 FLORA-5/GOG3035: chemo-immunotherapy (paclitaxel and carboplatin ± oregovomab) as front-line treatment for patients with ovarian cancer. A phase III double blind placebo controlled, global multicenter study

International journal of gynecological cancer, 2022-12, Vol.32 (Suppl 3), p.A233-A234

2022

Volltextzugriff (PDF)

TP032/#1532 Oregovomab and non-platinum single agent chemotherapy in parp inhibitor-resistant ovarian cancer patients not candidate for platinum retreatment: a multi-cohort phase II study (KGOG 3065/APGOT-OV6)

International journal of gynecological cancer, 2022-12, Vol.32 (Suppl 3), p.A239-A239

2022

Volltextzugriff (PDF)

TP012/#1530 Phase 2, single arm clinical trial to evaluate the safety and activity of oregovomab and niraparib in subjects with platinum sensitive recurrent ovarian cancer: flora-4

International journal of gynecological cancer, 2023-11, Vol.33 (Suppl 4), p.A251-A251

2023

Volltextzugriff (PDF)

TP015/#1539 A double-blind, placebo-controlled, phase II chemoimmunotherapy (Paclitaxel-carboplatin-oregovomab) vs chemotherapy (Paclitaxel-carboplatin-placebo) as neoadjuvant therapy in patients with advanced epithelial ovarian, fallopian tube or peritoneal carcinoma

International journal of gynecological cancer, 2023-11, Vol.33 (Suppl 4), p.A251-A251

2023

Volltextzugriff (PDF)

TP011/#1536 A double-blind placebo-controlled phase III chemo-immunotherapy (Paclitaxel-carboplatin-oregovomab [PCO]) vs chemotherapy (Paclitaxel-carboplatin-placebo [PCP]) in patients with newly diagnosed, advanced epithelial ovarian cancer (EOC): FLORA-5/GOG-3035 study

International journal of gynecological cancer, 2023-11, Vol.33 (Suppl 4), p.A250-A251

2023

Volltextzugriff (PDF)

Pharmacogenetics of SLCO1B1 gene and the impact of 1b and 15 haplotypes on irinotecan disposition in Asian cancer patients

Pharmacogenetics and genomics, 2006-09, Vol.16 (9), p.683-691

2006

Volltextzugriff (PDF)

Role of UGT1A16, UGT1A128 and ABCG2 c.421C>A polymorphisms in irinotecan‐induced neutropenia in Asian cancer patients

Cancer science, 2007-09, Vol.98 (9), p.1461-1467

2007

Volltextzugriff (PDF)

Semisynthesis and in vitro anticancer activities of andrographolide analogues

Phytochemistry (Oxford), 2007-03, Vol.68 (6), p.904-912

2007

Volltextzugriff (PDF)

Influence of APOE genotypes and VKORC1 haplotypes on warfarin dose requirements in Asian patients

British journal of clinical pharmacology, 2008-02, Vol.65 (2), p.260-264

2008

Volltextzugriff (PDF)

EGFR Intron 1 polymorphism in asian populations and its correlation with EGFR gene expression and amplification in breast tumour tissues

Cancer biology & therapy, 2006-11, Vol.5 (11), p.1445-1449

2006

Volltextzugriff (PDF)

Pharmacogenetics of SLCO1B1 : haplotypes, htSNPs and hepatic expression in three distinct Asian populations

European journal of clinical pharmacology, 2007-06, Vol.63 (6), p.555-563

2007

Volltextzugriff (PDF)

FLORA-5: A phase III double blind placebo controlled multicenter clinical study of front-line chemo-immunotherapy (paclitaxel and carboplatin +/- oregovomab) in patients with advanced epithelial ovarian cancer (GOG-3035) (298)

Gynecologic oncology, 2022-08, Vol.166, p.S157

2022

Volltextzugriff (PDF)

High incidence of allelic loss at 16q12.2 region spanning RB2/p130 gene in retinoblastoma

Cancer biology & therapy, 2009-04, Vol.8 (8), p.714-717

2009

Volltextzugriff (PDF)

Pharmacogenetics of SLCO1B1: haplotypes, htSNPs and hepatic expression in three distinct Asian populations

European journal of clinical pharmacology, 2007-08, Vol.63 (8), p.813-814

2007

Volltextzugriff (PDF)

14-Acetylandrographolide

Journal of chemical crystallography, 2006-02, Vol.36 (2), p.93-97

2006

Volltextzugriff (PDF)

Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients

Pharmacogenomics, 2007-06, Vol.8 (6), p.567-575

2007

Volltextzugriff (PDF)

Semisynthesis and cytotoxic activities of andrographolide analogues

Journal of enzyme inhibition and medicinal chemistry, 2006-04, Vol.21 (2), p.145-155

2006

Volltextzugriff (PDF)

High incidence of allelic loss at 16q12.2 region spanning RBL2/p130 gene in retinoblastoma

Cancer biology & therapy, 2009-04, Vol.8 (8), p.714-717

2009

Volltextzugriff (PDF)

Correspondence re: Cecchin et al., Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients. Clin Cancer Res 2005;11:6901-7

Clinical cancer research, 2006-03, Vol.12 (6), p.1942; author reply 1942-1942

2006

Volltextzugriff (PDF)

Novel

Pharmacogenomics, 2007-06, Vol.8 (6), p.567-575

2007

Volltextzugriff (PDF)

Semisynthesis and cytotoxic activities of andrographolide analogues: Erratum The Publishers would like to apologie for an error that occured on the title page of Journal of Enzyme and Medicinal Chemistry, April 2006; 21(2): 145-155. The correct title page is below

Journal of enzyme inhibition and medicinal chemistry, 2006-01, Vol.21 (3), p.327-327

2006

Volltextzugriff (PDF)

Semisynthesis and cytotoxic activities of andrographolide analogues

Journal of enzyme inhibition and medicinal chemistry, 2006-06, Vol.21 (3), p.327-327

2006

Volltextzugriff (PDF)

447 POSTER The impact of UGT1A128 and UGT1A16 on irinotecan-induced neutropenia in Asian cancer patients receiving weekly and three weekly irinotecan regimens

European journal of cancer supplements, 2006-11, Vol.4 (12), p.136

2006

Volltextzugriff (PDF)

3,19‐(2‐Bromobenzylidene)andrographolide

Acta crystallographica. Section E, Structure reports online, 2006-02, Vol.62 (2), p.o592-o594

2006

Volltextzugriff (PDF)

447 POSTER The impact of UGT1A1 28 and UGT1A1 6 on irinotecan-induced neutropenia in Asian cancer patients receiving weekly and three weekly irinotecan regimens

European journal of cancer supplements, 2006, Vol.4 (12), p.136-136

2006

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(26)
Berichte
(1)

Sprache

Englisch
(27)

Erscheinungsjahr

n.n

Thema

Science & Technology
(13)
Life Sciences & Biomedicine
(11)
Humans
(10)
Pharmacology & Pharmacy
(6)
Biological And Medical Sciences
(5)
Female
(5)
Medical Sciences
(5)
Oncology
(5)
Adult
(4)
Aged
(4)
Andrographolide
(4)
Chemotherapy
(4)
Genotype
(4)
Male
(4)
Middle Aged
(4)
Ovarian Cancer
(4)
Pharmacology. Drug Treatments
(4)
Antigens
(3)
Biochemistry & Molecular Biology
(3)
Camptothecin - Analogs & Derivatives
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

TP021/#1521 FLORA-5/GOG3035: chemo-immunotherapy (paclitaxel and carboplatin ± oregovomab) as front-line treatment for patients with ovarian cancer. A phase III double blind placebo controlled, global multicenter study

TP032/#1532 Oregovomab and non-platinum single agent chemotherapy in parp inhibitor-resistant ovarian cancer patients not candidate for platinum retreatment: a multi-cohort phase II study (KGOG 3065/APGOT-OV6)

TP012/#1530 Phase 2, single arm clinical trial to evaluate the safety and activity of oregovomab and niraparib in subjects with platinum sensitive recurrent ovarian cancer: flora-4

TP015/#1539 A double-blind, placebo-controlled, phase II chemoimmunotherapy (Paclitaxel-carboplatin-oregovomab) vs chemotherapy (Paclitaxel-carboplatin-placebo) as neoadjuvant therapy in patients with advanced epithelial ovarian, fallopian tube or peritoneal carcinoma

TP011/#1536 A double-blind placebo-controlled phase III chemo-immunotherapy (Paclitaxel-carboplatin-oregovomab [PCO]) vs chemotherapy (Paclitaxel-carboplatin-placebo [PCP]) in patients with newly diagnosed, advanced epithelial ovarian cancer (EOC): FLORA-5/GOG-3035 study

Pharmacogenetics of SLCO1B1 gene and the impact of 1b and 15 haplotypes on irinotecan disposition in Asian cancer patients

Role of UGT1A16, UGT1A128 and ABCG2 c.421C>A polymorphisms in irinotecan‐induced neutropenia in Asian cancer patients

Semisynthesis and in vitro anticancer activities of andrographolide analogues

Influence of APOE genotypes and VKORC1 haplotypes on warfarin dose requirements in Asian patients

EGFR Intron 1 polymorphism in asian populations and its correlation with EGFR gene expression and amplification in breast tumour tissues

Pharmacogenetics of SLCO1B1 : haplotypes, htSNPs and hepatic expression in three distinct Asian populations

FLORA-5: A phase III double blind placebo controlled multicenter clinical study of front-line chemo-immunotherapy (paclitaxel and carboplatin +/- oregovomab) in patients with advanced epithelial ovarian cancer (GOG-3035) (298)

High incidence of allelic loss at 16q12.2 region spanning RB2/p130 gene in retinoblastoma

Pharmacogenetics of SLCO1B1: haplotypes, htSNPs and hepatic expression in three distinct Asian populations

14-Acetylandrographolide

Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients

Semisynthesis and cytotoxic activities of andrographolide analogues

High incidence of allelic loss at 16q12.2 region spanning RBL2/p130 gene in retinoblastoma

Correspondence re: Cecchin et al., Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients. Clin Cancer Res 2005;11:6901-7

Novel

Semisynthesis and cytotoxic activities of andrographolide analogues: Erratum The Publishers would like to apologie for an error that occured on the title page of Journal of Enzyme and Medicinal Chemistry, April 2006; 21(2): 145-155. The correct title page is below

Semisynthesis and cytotoxic activities of andrographolide analogues

447 POSTER The impact of UGT1A128 and UGT1A16 on irinotecan-induced neutropenia in Asian cancer patients receiving weekly and three weekly irinotecan regimens

3,19‐(2‐Bromobenzylidene)andrographolide

447 POSTER The impact of UGT1A1 28 and UGT1A1 6 on irinotecan-induced neutropenia in Asian cancer patients receiving weekly and three weekly irinotecan regimens

Suchergebnisse filtern